ONE-YEAR FOLLOW-UP OUTCOMES OF TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION WITH AFLIBERCEPT

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacological Treatments

Background:

• Wet age-related macular degeneration (ARMD) is a leading cause of vision loss in older adults.
• Anti-vascular endothelial growth factor (anti-VEGF) therapy is a standard treatment for wet ARMD.
• Aflibercept is an anti-VEGF agent used to treat wet ARMD.

Purpose of the Study:

• To evaluate the one-year outcomes of aflibercept treatment in newly diagnosed wet ARMD patients.
• To assess changes in visual acuity and retinal thickness following aflibercept therapy.
• To determine the safety and efficacy of aflibercept in a real-world clinical setting.

Main Methods:

• Retrospective analysis of 28 eyes from 28 patients with newly diagnosed wet ARMD.
• Patients received aflibercept according to the summary of product characteristics (SPC) dosing regimen.
• Evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) via optical coherence tomography (OCT).

Main Results:

• Average BCVA improved from 61.5 to 68.1 ETDRS letters at one year, with 89.3% of eyes maintaining or improving vision.
• Average CRT decreased from 360.9 µm to 233.8 µm after one year.
• 25 eyes (89.3%) showed no signs of active pathology at the end of the study period, with no reported complications.

Conclusions:

• Aflibercept is effective and safe for treating newly diagnosed wet ARMD.
• Adherence to a fixed therapeutic regimen yields excellent clinical outcomes comparable to clinical trials.
• The study confirms aflibercept's role in managing wet ARMD in routine practice.